Toronto, ON – April 8, 2019
A recent Financial Post article prominently showcased two Canadian companies – Cyclica and Deep Genomics – who are at the forefront of applying Artificial Intelligence in the field of drug discovery and innovation.
The Financial Post Article, which appeared in the National Post on April 3, 2019, notes that “in partnership with companies including Merck, Bayer, Eurofarma and WuXi,” Cyclica is “using AI in conjunction with biophysics, statistics and big data to investigate how druds might act on multiple targets and disease pathways”.
Read the article here: https://nationalpost.com/news/filling-in-the-missing-pieces-how-ai-is-transforming-drug-discovery-development-and-innovation
About
Cyclica
Cyclica’s Ligand Express™ platform has been used and validated through third-party organizations to
develop safer and more efficacious therapeutics. Whether hypothetical,
pre-clinical, clinical, or FDA-approved, Cyclica offers insight and analysis
into a small molecule’s effect, in order to augment drug discovery pipelines
and efficiently take assets from bench-to-bedside. Ligand Express™ is unique in
that it is a drug-centric platform. It currently features PROBEx
(proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems
biology & drug-protein interactomes), and evaluates and compares small
molecules to predict how each will interact with the human body (i.e human
proteome). As such, Ligand Express™ provides value in finding novel desirable
or undesirable targets, which provides clients with polypharmacological
profiles that may identify unknown targets, prioritize lead candidates,
elucidate adverse effects and point to repurposing opportunities. In addition,
Cyclica’s proprietary database of structurally-characterized bacterial and
viral proteomes can be used to identify new treatments for infectious diseases.
https://cyclicarx.com/
About GreenSky Capital
GreenSky Capital Inc. is an award-winning Toronto-based investment firm that provides
investment and corporate financial advisory services to small and medium sized
technology firms. It is affiliated with the GreenSky Accelerator venture
capital funds. GreenSky looks for long-term partnerships with high growth
potential companies and dedicated entrepreneurs. GreenSky principals bring a
unique combination of experience in technology, law and finance into a
real-world context.
www.greenskycapital.com